1. Basic Information
Disease Protected Against
Haemophilus influenzae type b (Hib) is a bacterial pathogen that primarily affects children <5 years. Before vaccination, Hib was the leading cause of bacterial meningitis in U.S. children, as well as epiglottitis, septic arthritis, pneumonia, and bacteremia. Hib meningitis has a case-fatality rate of ~3–6% and causes permanent neurological sequelae (hearing loss, developmental delay) in 15–30% of survivors. Nontypeable H. influenzae (NTHi) strains, which are not covered by the Hib vaccine, cause otitis media and respiratory infections in children and adults but not invasive disease at the same rates.
CDC Recommended Schedule (U.S., 2025)
| Dose | Recommended Age | Notes |
|---|---|---|
| Dose 1 | 2 months | Minimum age 6 weeks |
| Dose 2 | 4 months | |
| Dose 3 (if needed) | 6 months | Depends on product (PedvaxHIB = 2-dose series; ActHIB/Hiberix/Pentacel/VAXELIS = 3-dose series) |
| Booster | 12–15 months | All products require a booster dose at 12–15 months |
Source: CDC ACIP, 2025 Child & Adolescent Immunization Schedule. Note: PedvaxHIB (Merck, PRP-OMP conjugate) requires only a 2-dose primary series at 2 and 4 months plus a booster at 12–15 months.
Licensed Products (U.S.)
- ActHIB® (Sanofi) — PRP-T conjugate (tetanus toxoid carrier). Licensed 1993.
- Hiberix® (GSK) — PRP-T conjugate. Licensed 2009, primarily for booster dose.
- PedvaxHIB® (Merck) — PRP-OMP conjugate (outer membrane protein carrier). Licensed 1989. 2-dose primary series.
- Combination vaccines: Pentacel (DTaP-IPV-Hib), VAXELIS (DTaP-IPV-Hib-HepB). Both use PRP-T conjugate.
2. Pre-Licensure Clinical Trial Data
The first Hib polysaccharide vaccine (unconjugated) was licensed in 1985 but was poorly immunogenic in infants <18 months. The first conjugate vaccine (PRP-D, ProHIBIT) was licensed in 1987. Current PRP-T and PRP-OMP conjugate vaccines were licensed between 1989–1993. Pivotal trials enrolled several thousand infants each.
| Metric | Data | Evidence Strength |
|---|---|---|
| Combined pre-licensure safety database | ~10,000+ infants across all conjugate products | Moderate |
| Efficacy (invasive Hib disease) | ~95–100% in clinical trials | Strong |
| Seroprotection (anti-PRP ≥0.15 µg/mL) | ~90–100% after primary series | Strong |
Most Common Adverse Reactions
| Reaction | Frequency (Approx.) |
|---|---|
| Injection site pain/tenderness | ~10–25% |
| Injection site redness/swelling | ~5–10% |
| Fever >38°C | ~5–15% |
| Irritability | ~15–30% |
| Drowsiness | ~10–20% |
Sources: Respective prescribing information; FDA review documents. Adverse reactions are generally mild and self-limited (1–3 days). Local reaction rates are higher when Hib is given as part of combination vaccines (Pentacel, VAXELIS).
Key Limitations
- No true placebo: Most trials used other vaccines as comparators due to ethical constraints, limiting absolute risk attribution.
- Combination products: Modern Hib vaccination is predominantly via combination vaccines (Pentacel, VAXELIS), making it difficult to isolate Hib-specific adverse events from those attributable to co-administered antigens (DTaP, IPV).
- Carrier protein effects: Different Hib conjugates use different carrier proteins (tetanus toxoid, OMP). The long-term safety implications of repeated carrier protein exposure in combination schedules are not fully characterized.
3. Post-Licensure Safety Data
VSD and VAERS
Hib vaccines have an extensive post-licensure safety record with >30 years of U.S. data. VSD and VAERS surveillance have not identified unexpected safety signals. Key findings:
- No association between Hib vaccination and serious adverse events, SIDS, or neurodevelopmental outcomes has been identified in VSD studies.
- VAERS data are consistent with clinical trial reactogenicity profiles. No confirmed safety signals beyond those identified in pre-licensure trials.
- IOM (2012) reviewed Hib vaccine and found evidence inadequate to accept or reject causality for most rare outcomes, reflecting the low frequency of adverse event reports and limited targeted post-licensure studies (relative to more controversial vaccines).
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (HiB (all Hib products combined)):
| Metric | Value |
|---|---|
| U.S. doses administered (2006–2022) | 159,451,493 |
| Total VAERS AE reports | 21,526 |
| AE reporting rate (per 100,000 doses) | 13.5 |
| Total death reports | 435 |
| Death reporting rate (per 100,000 doses) | 0.273 |
| AE-to-Death ratio | 50:1 |
Source: Halma MT, Varon J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4010005. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
- Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
- Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
- Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
- Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
- Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma MT, Varon J. DARE-SAFE: A data analysis and reporting engine for safety signal detection and pharmacovigilance. Pharmacoepidemiology. 2025;4(1):5. DOI: 10.3390/pharma4010005. CC BY 4.0.
4. Documented Adverse Events
▶ Strong Evidence
- Injection site reactions: Pain (10–25%), redness/swelling (5–10%). Mild, self-limited. Strong
- Fever: 5–15% (low-grade). Strong
- Irritability/drowsiness: 15–30%. Self-limited (1–2 days). Strong
- Anaphylaxis: ~1 per million doses (rare). Strong
▶ Published Evidence Does Not Support a Causal Association
- SIDS: No association. No Association
- Type 1 diabetes: Studied; no association found. No Association
5. Disease Prevention Benefits
| Metric | Pre-Vaccine Era | Post-Vaccine Era |
|---|---|---|
| Invasive Hib disease (annual, children <5) | ~20,000 cases (~40–100 per 100,000) | <50 cases (<1 per 100,000) — >99% reduction |
| Hib meningitis (annual) | ~12,000 cases; leading cause of acquired intellectual disability | <30 cases/year |
| Hib deaths (annual, children <5) | ~600–800 | <5/year |
Source: CDC Pink Book; MMWR. The Hib vaccine has near-eliminated invasive Hib disease in the U.S. Vaccination also reduces nasopharyngeal carriage, providing herd protection to unvaccinated children.
6. Evidence Summary
Hib conjugate vaccines have been in U.S. use for >35 years with a well-established safety and effectiveness profile. Pre-licensure trials were moderate in size but post-licensure data from national surveillance and VSD are extensive. The Hib vaccine is among the most effective in the pediatric schedule, with >99% reduction in invasive disease. No significant post-licensure safety signals have been identified.
| Domain | Evidence Grade |
|---|---|
| Invasive Hib disease prevention | Strong |
| Common adverse events | Strong |
| Rare adverse events | Moderate |
7. Key References
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012. nationalacademies.org
- CDC. Pink Book — Hib chapter. cdc.gov/pinkbook
- Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century. Clin Microbiol Rev. 2000;13(2):302–317.
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov